文献速递眼底病与葡萄膜炎

用于评估视网膜干细胞疗法的动物模型

Animal models for the evaluation of retinal stem cell therapies.
PubMed 文献 · Prog Retin Eye Res · 2025-04-14

视网膜变性(RD)可累及感光细胞(PR)或视网膜色素上皮(RPE),导致严重视力丧失。基于人多能干细胞(hPSC)的疗法有PR挽救和PR替代两种靶向策略,动物模型用于验证手术可行性、移植物存活和视觉功能恢复,但现有模型在复现临床免疫挑战和检测细微功能变化方面存在局限。

要点

  • hPSC疗法靶向策略包括PR挽救(移植RPE或神经祖细胞至视网膜下腔)和PR替代(移植干细胞来源的感光细胞样细胞或感光细胞祖细胞)。
  • RPE移植通过提供营养支持和维持视网膜完整性来保护感光细胞,尤其在年龄相关性黄斑变性(AMD)等疾病中。
  • 动物模型用于建立手术可行性、移植物存活和视觉功能恢复,但未能复现临床免疫挑战。

核心结论

  • 虽然已取得有希望的进展,但解决这些局限性对于将干细胞疗法转化为临床成功仍至关重要。

研究设计与样本

  • 综述,汇总当前关于干细胞移植方法、用于验证移植研究视觉获益的动物模型要求、特定疾病模型优势及其局限性的知识。

主要发现

  • RPE移植方法(如极化单层培养和支架为基础的方法)在增强移植物存活和整合方面显示出希望。
  • PRP通常从视网膜类器官(ROs)获得,替代来源如早期分化阶段或直接分化方案也被用于提高PRP生成的效率和可扩展性。
  • 挑战包括实现适当整合、形成外段、菊形团形成以及避免免疫排斥或致瘤性。
  • 啮齿类模型缺乏类黄斑结构,检测细微功能变化的可靠性有限;大型动物模型带来伦理、后勤和财务挑战。
  • 已开发免疫缺陷模型以尽量减少异种移植问题。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • RPE移植的局限性包括整合不一致、神经营养因子分泌可变以及非自体移植中的免疫排斥风险。
  • PR替代的挑战包括实现适当整合、形成外段、菊形团形成以及避免免疫排斥或致瘤性。
  • 动物模型未能复现临床免疫挑战。
  • 啮齿类模型缺乏类黄斑结构,检测细微功能变化的可靠性有限。
  • 大型动物模型带来伦理、后勤和财务挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Retinal degeneration (RD) diseases leading to severe vision loss can affect photoreceptors (PRs) that are responsible for phototransduction, or retinal pigmented epithelium (RPE) providing support for PRs. Human pluripotent stem cell (hPSC)-based therapies are a potential approach for restoration of retinal structure in patients with currently incurable RD diseases. Currently, there are two targeted hPSC therapeutics: PR rescue and PR replacement. PR rescue involves the transplantation of RPE or other neural progenitors into the subretinal space to slow down or prevent further RD. RPE transplantation plays a critical role in preserving photoreceptors by providing trophic support and maintaining retinal integrity, particularly in diseases like age-related macular degeneration (AMD). Advances in RPE transplantation methods, such as polarized monolayer cultures and scaffold-based approaches, have shown promise in enhancing graft survival and integration. However, limitations include inconsistent integration, variable neurotrophic factor secretion, and immune rejection risks in non-autologous transplants. In PR replacement, stem cell-derived photoreceptor-like cells or photoreceptor progenitors (PRP) obtained are transplanted into the eye. While PRPs are commonly obtained from retinal organoids (ROs), alternative sources, such as early differentiation stages or direct differentiation protocols, are also utilized to enhance the efficiency and scalability of PRP generation. Challenges include achieving proper integration, forming outer segments, rosette formation, and avoiding immune rejection or tumorigenicity. Various animal models that simulate human RD diseases are being used for establishing surgical feasibility, graft survival and visual functional recovery but fail to replicate clinical immune challenges. Rodent models lack macula-like structures and have limited reliability in detecting subtle functional changes, while larger animal models pose ethical, logistical, and financial challenges. Immunocompromised models have been developed for minimizing xenograft issues. Visual functional testing for efficacy includes optokinetic testing (OKN), electroretinography (ERG), and electrophysiological recordings from the retina and brain. These tests often fail to capture the complexity of human visual recovery, highlighting the need for advanced models and improved functional testing techniques. This review aims to aggregate current knowledge about approaches to stem cell transplantation, requirements of animal models chosen for validating vision benefits of transplantation studies, advantages of using specific disease models and their limitations. While promising strides have been made, addressing these limitations remains essential for translating stem cell-based therapies into clinical success.

来源:Prog Retin Eye Res,查看原文。版权归原作者所有。

引用

  1. Thomas BB, Rajendran Nair DS, Rahimian M, et al. Animal models for the evaluation of retinal stem cell therapies. Prog Retin Eye Res. 2025. PMID: 40239758. doi:10.1016/j.preteyeres.2025.101356

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。